Tebra vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Practice management platform for 130K independent physicians from Kareo+PatientPop merger; EHR, billing, and patient acquisition marketing for small practices competing with athenahealth.
About
Tebra (formerly Kareo + PatientPop) is a cloud-based practice management and digital health platform for independent healthcare practices — providing practice management software, electronic health records (EHR), billing and revenue cycle management, patient engagement, and healthcare marketing tools specifically designed for small independent physician practices. Formed through the merger of Kareo (practice management/billing) and PatientPop (healthcare marketing/patient acquisition) in 2022, Tebra serves approximately 130,000 healthcare providers at independent practices across primary care, mental health, dermatology, and specialty care.\n\nTebra's platform addresses the full operational needs of a small medical practice: EHR documentation with templates for common visit types, automated patient appointment reminders and forms, insurance eligibility verification and claims submission, payment collection from patients, and online reputation management (Google reviews, healthcare directory listings). The combined Kareo+PatientPop heritage means Tebra uniquely covers both the clinical and administrative workflow alongside the digital marketing capabilities independent practices need to attract new patients.\n\nIn 2025, Tebra competes in the small practice EHR and practice management market against athenahealth, drchrono, Jane App, and Practice Fusion for independent physician practice software. The independent practice market faces significant headwinds from hospital consolidation — independent physician practices have steadily been acquired into health system employment or affiliated networks, shrinking the addressable market. Tebra's 2025 strategy focuses on the growing behavioral health segment (mental health practices are growing and need modern practice management tools), telehealth integration (virtual visit capability within the EHR workflow), and improving revenue cycle management automation to help practices collect more of what they bill.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.